Low concentrations of recombinant activated factor VII normalize coagulation patterns by reversing the changes in viscoelastic testing parameters induced by abelacimab in vitro.

abelacimab (MAA868) - Novartis

http://www.ncbi.nlm.nih.gov/pubmed/40837022

Dan Bloomfield; Debra Freedholm; Jean M Connors; Klaus Peter Hoffmann; Serge Côté; Yasser Khder

Aug 21, 2025